Clinical Trials
457 trialsA Phase I, Open-Label, Multi-center Study to Assess the Safety, Tolerability and Pharmacokinetics of AZD6244 (ARRY-142886)
AstraZeneca
Vaccination of Patients With Renal Cell Cancer With Dendritic Cell Tumor Fusions and GM-CSF
Beth Israel Deaconess Medical Center
KCC-S
University of Utah
Study of Kidney Tumors in Younger Patients
Children's Oncology Group
IRMK01
University Hospital, Bordeaux
Breathomics as Predictive Biomarker for Checkpoint Inhibitor Response
University Health Network, Toronto
SLM + Axitinib for Clear Cell RCC
University of Iowa
Enhancing Readability of Lay Abstracts and Summaries for Medical Knowledge Using Generative Artificial Intelligence (BRIDGE AI 3)
University of Southern California
FRISC
Centre Hospitalier Universitaire, Amiens
Sunitinib in Treating Patients With Kidney Cancer That Has Spread to the Brain
Institut Claudius Regaud
Risk of Scrotal Hydroceles After Nephrectomy For Kidney Cancer
London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's
Interleukin-2 and Pembrolizumab for Metastatic Kidney Cancer
H. Lee Moffitt Cancer Center and Research Institute
KIDCaD
Charles University, Czech Republic
Pembrolizumab (Anti-PD-1) and AMG386 (Angiopoietin-2 (Ang-2) in Patients With Advanced Solid Tumor
Dana-Farber Cancer Institute
A Study to Learn About the First and Later Lines of Medicines in Treating People With Metastatic Renal Cell Carcinoma (mRCC).
Pfizer
Efficacy and Safety of VasoClip® vs. WeckClip® for Robotic Urologic Surgery
Incheon St.Mary's Hospital
Navigated Partial Nephrectomy
The Netherlands Cancer Institute
IMPLICATION
Centre Hospitalier Universitaire de Besancon
Evaluating Length of Treatment With PD-1/PD-L1 Inhibitor in Advanced Solid Tumors
University of Pittsburgh
GenCInibs-Suni
Centre Hospitalier Universitaire de Nīmes
Feasibility of a Smart-Phone App for Patients With Advanced Renal Cell Carcinoma Undergoing Combination Immunotherapy
H. Lee Moffitt Cancer Center and Research Institute
CAIN
HistoSonics, Inc.
Study of CHS-388 (Formerly Known as SRF388) in Patients With Advanced Solid Tumors
Coherus Oncology, Inc.
AYAConnect
UNC Lineberger Comprehensive Cancer Center
CALM: Managing Distress in Malignant Brain Cancer
Virginia Commonwealth University
A Comparison of Methods for Assisting Needle Angle Selection During Image-guided Tissue Biopsy
National Institutes of Health Clinical Center (CC)
Clinical Registry for Oligometastic Disease, Consolidation Therapy, Debulking Prior to Chemotherapy, or Re-Irradiation
University of Texas Southwestern Medical Center
S0931
SWOG Cancer Research Network
RSR-1
Hospices Civils de Lyon
EARN
Washington University School of Medicine
DELFI-L101
Delfi Diagnostics Inc.
JAVELIN Renal 101
Pfizer
Serial Ultrasound in Metastatic Renal Cell Carcinoma (mRCC)
Stanford University
CheckMate 7C9
Bristol-Myers Squibb
A Study of Autogene Cevumeran (RO7198457) as a Single Agent and in Combination With Atezolizumab in Participants With Locally Advanced or Metastatic Tumors
Genentech, Inc.
PRIORITY
Institut Bergonié
P-NeLoP
University Hospital, Bordeaux
Talazoparib and Axitinib for People With Previously Treated Advanced Kidney Cancer
Memorial Sloan Kettering Cancer Center
Genomic Testing and Resulting Medical Decisions
Arbeitsgemeinschaft medikamentoese Tumortherapie
SOGUGCOVID
Spanish Oncology Genito-Urinary Group
Robot-assisted Partial Nephrectomy With and Without Mixed Reality (REALITATEM Study)
Hospital Moinhos de Vento
Nephrogreen
Birmingham Women's and Children's NHS Foundation Trust
Preliminary Evaluation of Uptake of [68Ga]P16-093 in Metastatic Prostate and Renal Cancer
Five Eleven Pharma, Inc.
A Phase II Study of Bevacizumab and Erlotinib in Subjects With Advanced Hereditary Leiomyomatosis and Renal Cell Cancer (HLRCC) or Sporadic Papillary Renal Cell Cancer
National Institutes of Health Clinical Center (CC)
CRYO-BO-2021
IRCCS Azienda Ospedaliero-Universitaria di Bologna
Study of Atezolizumab + Bevacizumab in Patients With Advanced Non-Clear Cell Renal Cell Carcinoma
Dana-Farber Cancer Institute
Clinical-pathological Characterization and Outcomes of Renal Cell Carcinoma in Latin American
Latin American Cooperative Oncology Group
HERO
Rutgers, The State University of New Jersey
CP-Renal
University Hospital, Strasbourg, France
CheckMate 914
Bristol-Myers Squibb